Ezetimibe 10 mg + rosuvastatin 2.5 mg versus rosuvastatin 5 mg for hypercholesterolemia in patients with type 2 diabetes
Not Applicable
- Conditions
- Hypercholesterolemic patients with type 2 diabetes.
- Registration Number
- JPRN-UMIN000011005
- Lead Sponsor
- First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of familial hypercholesterolemia, patients who have developed stroke or ischemic heart disease within the past six months, patients with liver failure (ALT and/or AST >80 IU/L) or kidney failure (serum creatinine >1.3 mg/dL), patients using insulin, patients who are pregnant or could possibly become pregnant, and patients who are breast feeding are excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is set as the percent change of LDL-C after 12 weeks compared with baseline.
- Secondary Outcome Measures
Name Time Method